10 likes | 159 Views
Table 1 Evidence supporting the role of complement dysregulation and the benefit of C5 blockade in aHUS and C3G. Zuber, J. et al. (2012) Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies Nat. Rev. Nephrol. doi:10.1038/nrneph.2012.214.
E N D
Table 1Evidence supporting the role of complement dysregulation and the benefit of C5 blockade in aHUS and C3G Zuber, J. et al.(2012) Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies Nat. Rev. Nephrol.doi:10.1038/nrneph.2012.214